Open-Label FURI Study, Showing Oral Ibrexafungerp’s Ability to Treat Refractory Fungal Infections and to Provide an Alternative to Long-Term IV Therapies

Analysis of first 20 patients confirms clinical antifungal activity of oral ibrexafungerp in patients with difficult-to-treat mucocutaneous and invasive fungal infections.

Source: Scinexis

Healthy Patients  

What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!

Keep me informed